U.S. Capital Wealth Advisors LLC Has $4.83 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

U.S. Capital Wealth Advisors LLC cut its stake in Amgen Inc. (NASDAQ:AMGN) by 18.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,765 shares of the medical research company’s stock after selling 3,684 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Amgen were worth $4,829,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. International Assets Investment Management LLC bought a new position in shares of Amgen in the 4th quarter valued at about $4,589,900,000. Assenagon Asset Management S.A. raised its position in shares of Amgen by 486.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 899,232 shares of the medical research company’s stock valued at $258,997,000 after acquiring an additional 745,929 shares during the last quarter. abrdn plc lifted its stake in shares of Amgen by 150.4% in the 4th quarter. abrdn plc now owns 1,043,609 shares of the medical research company’s stock valued at $300,580,000 after purchasing an additional 626,810 shares during the period. Los Angeles Capital Management LLC boosted its position in shares of Amgen by 111.9% in the 4th quarter. Los Angeles Capital Management LLC now owns 989,061 shares of the medical research company’s stock worth $284,869,000 after purchasing an additional 522,367 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in Amgen by 11.4% in the third quarter. Royal Bank of Canada now owns 5,079,677 shares of the medical research company’s stock valued at $1,365,213,000 after purchasing an additional 518,689 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on AMGN shares. Truist Financial reissued a “buy” rating and set a $320.00 price objective on shares of Amgen in a research note on Friday, April 12th. Raymond James assumed coverage on Amgen in a report on Thursday, March 28th. They set a “market perform” rating on the stock. Morgan Stanley raised their price target on Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a research report on Friday. TD Cowen reduced their target price on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. Finally, BMO Capital Markets lifted their price target on Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a research note on Friday. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $305.05.

Amgen Price Performance

NASDAQ AMGN traded up $32.90 during midday trading on Friday, hitting $311.29. The company had a trading volume of 9,644,682 shares, compared to its average volume of 2,279,398. The company has a market capitalization of $166.97 billion, a PE ratio of 44.47, a P/E/G ratio of 2.69 and a beta of 0.60. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The firm has a 50-day moving average price of $274.95 and a 200-day moving average price of $281.50.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. The firm had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 145.62%. The business’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same period in the prior year, the company posted $3.98 earnings per share. As a group, analysts anticipate that Amgen Inc. will post 19.43 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 2.89%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is presently 128.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.